MX2024006743A - Unidad de union a antigeno ccr8 y usos de los mismos. - Google Patents
Unidad de union a antigeno ccr8 y usos de los mismos.Info
- Publication number
- MX2024006743A MX2024006743A MX2024006743A MX2024006743A MX2024006743A MX 2024006743 A MX2024006743 A MX 2024006743A MX 2024006743 A MX2024006743 A MX 2024006743A MX 2024006743 A MX2024006743 A MX 2024006743A MX 2024006743 A MX2024006743 A MX 2024006743A
- Authority
- MX
- Mexico
- Prior art keywords
- ccr8
- antigen binding
- binding unit
- antibody
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021134930 | 2021-12-02 | ||
| PCT/CN2022/136276 WO2023098888A1 (en) | 2021-12-02 | 2022-12-02 | Ccr8 antigen binding unit and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006743A true MX2024006743A (es) | 2024-08-27 |
Family
ID=86611552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006743A MX2024006743A (es) | 2021-12-02 | 2022-12-02 | Unidad de union a antigeno ccr8 y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250034266A1 (https=) |
| EP (1) | EP4441098A4 (https=) |
| JP (1) | JP2024541680A (https=) |
| KR (1) | KR20240112929A (https=) |
| CN (1) | CN119072494A (https=) |
| AU (1) | AU2022400921A1 (https=) |
| CA (1) | CA3239784A1 (https=) |
| IL (1) | IL313177A (https=) |
| MX (1) | MX2024006743A (https=) |
| TW (1) | TW202342533A (https=) |
| WO (1) | WO2023098888A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| WO2024240224A1 (zh) * | 2023-05-23 | 2024-11-28 | 再鼎医药(上海)有限公司 | 包含抗ccr8抗体的制剂及其用途 |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN120230205A (zh) * | 2023-12-29 | 2025-07-01 | 苏州泽璟生物制药股份有限公司 | 包含ccr8抗原结合结构域的多特异性抗体 |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| US10087259B1 (en) * | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| CN110835371A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8单克隆抗体及其应用 |
| WO2020138489A1 (ja) * | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
| TWI890283B (zh) * | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| AU2021244200A1 (en) * | 2020-03-23 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-CCR8 antibodies for treating cancer |
| TW202216771A (zh) * | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
-
2022
- 2022-12-02 US US18/715,739 patent/US20250034266A1/en active Pending
- 2022-12-02 CA CA3239784A patent/CA3239784A1/en active Pending
- 2022-12-02 KR KR1020247021902A patent/KR20240112929A/ko active Pending
- 2022-12-02 WO PCT/CN2022/136276 patent/WO2023098888A1/en not_active Ceased
- 2022-12-02 CN CN202280080188.8A patent/CN119072494A/zh active Pending
- 2022-12-02 IL IL313177A patent/IL313177A/en unknown
- 2022-12-02 AU AU2022400921A patent/AU2022400921A1/en active Pending
- 2022-12-02 MX MX2024006743A patent/MX2024006743A/es unknown
- 2022-12-02 TW TW111146368A patent/TW202342533A/zh unknown
- 2022-12-02 EP EP22900692.9A patent/EP4441098A4/en active Pending
- 2022-12-02 JP JP2024533211A patent/JP2024541680A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022400921A1 (en) | 2024-06-27 |
| CA3239784A1 (en) | 2023-06-08 |
| KR20240112929A (ko) | 2024-07-19 |
| EP4441098A4 (en) | 2026-03-04 |
| JP2024541680A (ja) | 2024-11-08 |
| EP4441098A1 (en) | 2024-10-09 |
| TW202342533A (zh) | 2023-11-01 |
| WO2023098888A1 (en) | 2023-06-08 |
| US20250034266A1 (en) | 2025-01-30 |
| IL313177A (en) | 2024-07-01 |
| CN119072494A (zh) | 2024-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006743A (es) | Unidad de union a antigeno ccr8 y usos de los mismos. | |
| JOP20220070A1 (ar) | مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها | |
| JOP20210289A1 (ar) | مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| EA202190535A1 (ru) | Бифункциональное антитело против pd-1 и против vegfa, его фармацевтическая композиция и его применение | |
| MX2024007724A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado | |
| MX2022015374A (es) | Conjugados de anticuerpo anti antigeno de maduracion de linfocitos b (bcma)-farmaco y metodos de uso. | |
| MY208638A (en) | Anti-steap1 antigen-binding protein | |
| MY207205A (en) | Cd3 antibody and pharmaceutical use thereof | |
| MX2022016254A (es) | Terapia de combinación de inmunooncología con conjugados de il-2 y anticuerpos anti-egfr. | |
| EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
| CR20230128A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
| SA520420225B1 (ar) | cMET مترافقات عقار من عوامل رابطة أحادية النسيلة من واستخداماتها | |
| MX2024015391A (es) | Molecula de union a antigeno que se une especificamente a dll3 y cd3, y su uso farmaceutico | |
| MX2025002569A (es) | Anticuerpos anti-trop2/egfr y usos de estos | |
| CL2025002617A1 (es) | Conjugados anticuerpo-fármaco administrados por vía subcutánea para el uso en el tratamiento del cáncer | |
| ZA202309150B (en) | Antibody against nkp46 and application of antibody | |
| CL2025001502A1 (es) | Conjugados anticuerpo-fármaco anti-cea y métodos de uso | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| MX2025001452A (es) | Anticuerpos anti-ccr8 y metodos de uso | |
| CO2023017609A2 (es) | Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso | |
| JOP20230112A1 (ar) | أجسام مضادة لـ cd48، متقارنات الجسم المضاد مع العقار، واستخداماتها | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
| MX2024009292A (es) | Anticuerpos anti-her2/trop2 y usos de los mismos. | |
| MX2021009189A (es) | Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer. |